Summary:

The company is mainly engaged in the manufacture and sale of biochemical pharmaceuticals, technology solutions services and real estate development. Its key biochemical pharmaceutical products include clindamycin phosphate, potassium magnesium aspartate and water-soluble vitamins. The company has a number of subsidiaries, namely Shandong Huatai Pharmaceutical Co. Ltd, Shenzhen Wuzhou Medicine Co. Ltd, Wuhan Software Co. Ltd and Beijing Guonong Zhiye Co. Ltd. In 200 ... more

Exchange Filings:

• 5 Mln Restricted Shares to be Tradable (2008-08-26) more
• RMB 2.8-RMB 3.5 Mln Net Loss Projected (2008-08-20) more
• Administrative Rules for Related-party Transactions (2008-08-20) more
• Management Rules for Information Disclosure (2008-08-20) more
• 2008 Semiannual Report Financial Highlights (2008-08-20) more
• 2008 Semiannual Report Approved by Board (2008-08-20) more

Relevant Media Reports:

• HSI Properties Index Stocks Drop Up to 3.6% (2008-08-01) more